Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 2

Expert review on coronary calcium

Authors Matthew J Budoff, Khawar M Gul

Published 11 April 2008 Volume 2008:4(2) Pages 315—324

DOI http://dx.doi.org/10.2147/VHRM.S1160

Matthew J Budoff, Khawar M Gul

Division of Cardiology, Saint John’s Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, California, USA

Abstract: While there is no doubt that high risk patients (those with >20% ten year risk of future cardiovascular event) need more aggressive preventive therapy, a majority of cardiovascular events occur in individuals at intermediate risk (10%–20% ten year risk). Accurate risk assessment may be helpful in decreasing cardiovascular events through more appropriate targeting of preventive measures. It has been suggested that traditional risk assessment may be refined with the selective use of coronary artery calcium (CAC) or other methods of subclinical atherosclerosis measurement. Coronary calcification is a marker of atherosclerosis that can be quantified with the use of cardiac CT and it is proportional to the extent and severity of atherosclerotic disease. The published studies demonstrate a high sensitivity of CAC for the presence of coronary artery disease but a lower specificity for obstructive CAD depending on the magnitude of the CAC. Several large clinical trials found clear, incremental predictive value of CAC over the Framingham risk score when used in asymptomatic patients. Based on multiple observational studies, patients with increased plaque burdens (increased CAC) are approximately ten times more likely to suffer a cardiac event over the next 3–5 years. Coronary calcium scores have outperformed conventional risk factors, highly sensitive C-reactive protein (CRP) and carotid intima media thickness (IMT) as a predictor of cardiovascular events. The relevant prognostic information obtained may be useful to initiate or intensify appropriate treatment strategies to slow the progression of atherosclerotic vascular disease. Current data suggests intermediate risk patients may benefit most from further risk stratification with cardiac CT, as CAC testing is effective at identifying increased risk and in motivating effective behavioral changes. This article reviews information pertaining to the clinical use of CAC for assessing coronary atherosclerosis as a useful predictor of coronary artery disease (CAD) in certain population of patients.

Keywords: computed tomography, electron beam, prognosis, review, coronary artery calcification, calcium score, atherosclerosis, multi-detector computed tomography

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Mild and moderate pre-dialysis chronic kidney disease is associated with increased coronary artery calcium

Roy SK, Cespedes A, Li D, Choi TY, Budoff MJ

Vascular Health and Risk Management 2011, 7:719-724

Published Date: 2 December 2011

Readers of this article also read:

Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer

Jin K, Luo G, Xiao Z, Liu Z, Liu C, Ji S, Xu J, Liu L, Long J, Ni Q, Yu X

Drug Design, Development and Therapy 2015, 9:1247-1255

Published Date: 26 February 2015

Design, synthesis, and anticancer activity of novel berberine derivatives prepared via CuAAC “click” chemistry as potential anticancer agents

Jin X, Yan TH, Yan L, Li Q, Wang RL, Hu ZL, Jiang YY, Sun QY, Cao YB

Drug Design, Development and Therapy 2014, 8:1047-1059

Published Date: 6 August 2014

Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil

Shi F, Zhao JH, Liu Y, Wang Z, Zhang YT, Feng NP

International Journal of Nanomedicine 2012, 7:2033-2043

Published Date: 17 April 2012

Comparison of outcome in 1809 patients treated with drug-eluting stents or bare-metal stents in a real-world setting

Vogt A, Schoelmerich A, Pollner F, Schlitt M, Raaz U, Maegdefessel L, Reindl I, Buerke M, Werdan K, Schlitt A

Vascular Health and Risk Management 2011, 7:693-699

Published Date: 22 November 2011

Exercise electrocardiographic responses and serum cystatin C levels among metabolic syndrome patients without overt diabetes mellitus

Asli Tanindi, Hilal Olgun, Ayse Tuncel, et al

Vascular Health and Risk Management 2011, 7:59-65

Published Date: 6 February 2011

Modern role for clopidogrel in management of atrial fibrillation and stroke reduction

Lars Maegdefessel, Junya Azuma, Philip S Tsao

Vascular Health and Risk Management 2010, 6:95-103

Published Date: 26 February 2010

Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation

Peter Deibert, Carola Xander, Hubert E Blum, et al

Core Evidence 2009, 4:247-258

Published Date: 11 December 2009

Prevalence and component analysis of metabolic syndrome: An Indian atherosclerosis research study perspective

Saikat Kanjilal, Jayashree Shanker, Veena S Rao, Natesha B Khadrinarasimhaih, Manjari Mukherjee, et al

Vascular Health and Risk Management 2008, 4:189-197

Published Date: 8 February 2008